EN: Which drug prevents worsening of paroxysmal atrial fibrillation: verapamil or metoprolol?NL: Welk medicijn voorkomt het hardnekkiger worden van paroxismaal atriumfibrilleren: verapamil of metoprolol?
- Conditions
- EN: atrial fibrillation, progression, verapamil, metoprolol<br /><br />NL: atriumfibrilleren, progressie, verapamil, metoprolol
- Registration Number
- NL-OMON27565
- Lead Sponsor
- Martini ziekenhuis Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
In order to be eligible to participate in this trial, a subject must meet all of the following criteria:
Patients (age > 18) with symptomatic paroxysmal AF with an indication for rate control medication who participate in the RACE 5 registry. Patients must be able and willing to sign informed consent for the randomised study.
Exclusion Criteria
Exclusion criteria are (history of) persistent AF, previous adverse effects to the study drugs, contra-indication for the study drugs (i.e. heart failure with reduced ejection fraction, symptomatic hypotension, atrioventricular conduction disturbance, severe asthma/COPD), history of pulmonary vein isolation (PVI), pregnancy and breastfeeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome variable is incidence of AF progression from paroxysmal to persistent AF or the need for PVI.
- Secondary Outcome Measures
Name Time Method Main secondary outcome variables are AF burden, heart rate, exercise tolerance, symptom severity, quality of life, and costs.